Peptide Database

Victoza · Saxenda

Liraglutide is a once-daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and obesity (Saxenda). It achieves fatty acid attachment to albumin for extended half-life, enabling daily dosing. The LEADER trial established significant cardiovascular mortality benefit in high-risk patients, and research continues into neuroprotective and anti-inflammatory properties beyond metabolic indications.

Sandostatin · SMS 201-995

Octreotide is a synthetic 8-amino-acid somatostatin analog with a much longer half-life than native somatostatin. FDA-approved for acromegaly, carcinoid syndrome, VIPomas, and variceal bleeding, it is also used off-label for Cushing's disease, thyroid cancer, and refractory diarrhea. Long-acting release (LAR) formulations allow monthly dosing. It is among the most clinically important peptide drugs in endocrinology.

SRIF · Somatotropin Release-Inhibiting Factor

Somatostatin is a 14-amino-acid cyclic peptide and the primary endogenous inhibitor of growth hormone secretion. It also inhibits insulin, glucagon, gastrin, cholecystokinin, and secretin release, slows GI motility, and reduces splanchnic blood flow. Its short half-life drove the development of longer-acting analogs (octreotide, lanreotide) used clinically for acromegaly, neuroendocrine tumors, and GI bleeding.